Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action
Provided By PR Newswire
Last update: Apr 24, 2025
ASCO data expected to highlight how pelareorep activates immune responses in pancreatic cancer patients
Ongoing updates support potential of pelareorep combination therapies in one of the deadliest and hardest-to-treat cancers
Read more at prnewswire.com
